Panagora Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Panagora Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-59,146	Closed	-$153K	–	2503
2018 Q4	$153K	Buy	59,146 +46,115	+354%	+$157K	﹤0.01%	1705
2018 Q3	$57K	Sell	13,031 -37,116	-74%	-$200K	﹤0.01%	1997
2018 Q2	$307K	Sell	50,147 -35,692	-42%	-$250K	﹤0.01%	1516
2018 Q1	$626K	Buy	85,839 +67,736	+374%	+$596K	﹤0.01%	1321
2017 Q4	$148K	Sell	18,103 -469	-3%	-$4.4K	﹤0.01%	1759
2017 Q3	$195K	Buy	+18,572	New	+$177K	﹤0.01%	1690
2016 Q1	–	Sell	-5,901	Closed	-$72K	–	2293
2015 Q4	$72K	Buy	5,901 +3,662	+164%	+$57.1K	﹤0.01%	1882
2015 Q3	$37K	Sell	2,239 -1,623	-42%	-$35.7K	﹤0.01%	2056
2015 Q2	$82K	Buy	+3,862	New	+$69.3K	﹤0.01%	2010

Other funds holding AVDL

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Panagora Asset Management's AVDL Position: Q1 2019 in Review

Panagora Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2019, closing a stake of 59,146 shares — an estimated $153K sold.

Panagora Asset Management first reported a position in AVDL in Q2 2015 and held it in 9 quarters. The position peaked at $626K in Q1 2018. 49 funds tracked by Wall St. Rank hold AVDL as of Q1 2019.

Panagora Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Panagora Asset Management sold 59,146 Avadel Pharmaceuticals shares in Q1 2019, an estimated $153K.
Panagora Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2015 and held it in 9 quarters.
Panagora Asset Management's Avadel Pharmaceuticals position peaked at $626K in Q1 2018.
49 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2019.

Based on Panagora Asset Management's 13F filing for Q1 2019, filed 15 May 2019.